A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)
NCT ID: NCT01318434
Last Updated: 2015-12-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2/PHASE3
342 participants
INTERVENTIONAL
2011-02-28
2013-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
EB-1010 25 mg BID
Experimental Active
EB-1010 25mg BID
capsule once daily
EB-1010 50 mg BID
Experimental Active
EB-1010 50mg BID
Experimental Active
SSRI/SNRI
Active Comparator
SSRI Active
Active Comparator
EB-1010 0 mg BID
Placebo comparator
Placebo
Placebo comparator
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
EB-1010 25mg BID
capsule once daily
SSRI Active
Active Comparator
EB-1010 50mg BID
Experimental Active
Placebo
Placebo comparator
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients must be able to understand the nature of the study, agree to comply with the prescribed dosage regimens, report for regularly scheduled office visits, and communicate to study personnel about adverse events and concomitant medication use.
* Patients with a diagnosis of major depressive episode as defined by DSM-IV-TR criteria, based on the SCID-CT29; their major depressive episode must be deemed "valid" using the SAFER criteria interview24 administered by remote, independent raters.
* Patients who have reported a history for the current depressive episode of an inadequate response to 1 and no more than 1 adequate SSRI or SNRI treatment. An inadequate response is defined as less than a 50% reduction in depressive symptom severity, as assessed by the MGH ATRQ administered by remote, independent raters. An adequate trial is defined as an antidepressant treatment for at least 8 weeks duration at least at the minimum dose as specified in the MGH ATRQ.
* Patients must have a 17-item Hamilton Rating Scale for Depression (HAM-D-17) (whose score is derived from the HAM-D-28)20 score ≥ 18 during the screening phase to qualify for inclusion. The HAM-D-28 will be administered by the study clinicians at the screening and baseline visits, and by remote, independent raters during the screening phase at the time of the SAFER interview.
* Patients must have a Body Mass Index (BMI) of approximately 18-40.
* Patients must be able to be reliably rated on the psychiatric scales required by the protocol based on Investigator's judgment.
* Patients must be able to understand and read English.
* Placebo non-responders are defined as those patients who failed to achieve at least a 50% decrease in their MADRS score at visit 8 (Week 6), AND have a MADRS score of = or \> 16 at visit 8 (Week 6)
* Men and women, ages 18 to 65 inclusive.
* Meet DSM-IV-TR criteria (by Structured Clinical Interview for DSM-IV-TR - SCID-CT) for MDD, current.
* Treated with one of the allowed SSRIs or SNRIs at adequate doses (defined as 20mg/day or more of citalopram; 10 mg/day or more of escitalopram, 50mg/day or more of sertraline; 125 mg/day or more of venlafaxine; 60 mg/day or more of duloxetine) during the current episode for at least 8 weeks, with the same, adequate dose over the last 4 weeks.
* Between the screen and baseline visits, patients must be documented to have less than a 25% reduction in QIDS-SR score.
* Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 4 weeks after the last dose of investigational product in such a manner that the risk of pregnancy is minimized. Adequate methods are defined as those which result in a low failure rate (i.e., less than 1% per year) when used consistently and correctly such as implants, injectable or patch hormonal contraception, oral contraceptives, an IUD, double-barrier contraception, sexual abstinence. Form of birth control will be documented at screening and baseline.
WOCBP include any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or is not postmenopausal (defined as amenorrhea ³ 12 consecutive months); or women on hormone replacement therapy \[HRT\] with documented serum follicle stimulating hormone \[FSH\] level \> 35 mIU/mL). Even women who are using oral contraceptives, other hormonal contraceptives (vaginal products, skin patches, or implanted or injectable products), or mechanical products such as an intrauterine device or barrier methods (diaphragm, condoms, spermicides) to prevent pregnancy, or are practicing abstinence or where their partner is sterile (e.g., vasectomy) should be considered to be of childbearing potential. WOCBP must have a negative urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 72 hours prior to the start of investigational product.
Exclusion Criteria
* WOCBP using a prohibited contraceptive method that does not meet established and acceptable medical standards.
* Women who are pregnant or breastfeeding.
* Women with a positive pregnancy test on enrollment or prior to investigational product administration.
* Sexually active fertile men not using effective birth control if their partners are WOCBP.
* Patients who do not report any prior inadequate response (equal or greater than 50% decrease in depressive symptom severity) or report an inadequate response (less than 50% decrease in depressive symptom severity) to more than 1 prior adequate trials of antidepressant treatments during the current depressive episode (including monotherapy treatment and distinct combination regimens) at a therapeutic dose (as defined by the MGH ATRQ)22-23 and for an adequate duration (minimum 6 weeks for any monotherapy).
* Patients who report treatment with adjunctive medication (buspirone, atypical antipsychotics, lithium) to their antidepressant therapy for a minimum of 4 weeks during the current depressive episode.
* Patients with a current need for involuntary commitment or who have been hospitalized within 4 weeks of the Screening Visit for the current major depressive episode.
* Subjects with other DSM-IV-TR Axis I disorders other than Generalized Anxiety Disorder (GAD: 300.02), Social Anxiety Disorder (300.23), or Specific Phobia (300.29). Subjects with co-morbid GAD, Social Anxiety Disorder, or Specific Phobia are ineligible if the co-morbid condition is clinically unstable, requires treatment, or has been the primary focus of treatment within the 6 month period prior to screening. More specifically, patients who have a current Axis I diagnosis
* Patients experiencing hallucinations, delusions, or any psychotic symptomatology in the current or any previous depressive episode.
* Patients who have met DSM-IV-TR criteria for any significant substance use disorder within the past six months, based on the SCID-CT.
* Patients receiving new-onset psychotherapy and/or somatic therapy (light therapy, trans-cranial magnetic stimulation) within 6 weeks of screening, or at any time during participation in the trial.
* Patients who, in the opinion of the Investigator, are actively suicidal and at significant risk for suicide.
* Patients who have participated in any clinical trial with an investigational drug or device within the past month.
* Patients who routinely perform shift work and whose sleep-wake cycle is frequently changed because of their work.
* Patients who have received ECT in the past 20 years or Vagal Nerve/Deep Brain Stimulation during their lifetime.
* Unstable medical illness including, cardiovascular, hepatic, renal, respiratory, endocrine, neurological, or hematological disease.
* Subjects with evidence or history of significant neurological disorder, including head trauma with loss of consciousness, history of stroke, Parkinson's disease, epilepsy disorder, conditions that lower seizure threshold, seizures of any etiology (including substance or drug withdrawal), who are taking medications to control seizures, or who have increased risk of seizures as evidenced by history of EEG with epileptiform activity (with the exception of juvenile febrile seizures).
* Subjects who are known to have AIDS or to be HIV positive.
* Patients with a significant history of drug or food allergy or hypersensitivity. Specifically, patients who report a history of drug-induced and/or food-induced asthma, facial-swelling, tongue swelling, angioedema, urticaria, stridor, hives, epiglottis swelling, recurrent skin rashes, toxic epidermal necrolysis, or Stevens-Johnson Syndrome.
* Patients who, in the Investigator's judgment represent a significant risk of committing suicide during the course of the trial based on history or evaluation of current mental status. Patients with significant hostility and history of aggressive acts who, in the Investigator's judgment, represent a significant risk of committing violent acts during the course of the trial based on history or evaluation of current mental status.
* Patients who have a history or evidence of a medical condition that would expose them to an undue risk of a significant adverse event or interfere with assessments of safety or efficacy during the course of the trial.
* Patients with thyroid pathology (unless condition has been stabilized with medications for at least the past three months).
* Patients with a lifetime history of serotonin syndrome.
* Patients with a significant history of a seizure disorder.
* Patients who have received a vaccination in the past three months.
* Patients with a recent (within two weeks) viral or systemic illness.
* Patients with current skin rashes.
* Patients who have recently (within two weeks) begun any medications.
* Patients who have a positive urine drug screen which cannot be explained by prescribed medications.
* Patients with AST and/or ALT \>2x ULN at the screening visit.
* Patients with abnormal thyroid-stimulating hormone (TSH) concentrations or positive hepatitis tests.
* Patients with clinically significant laboratory abnormalities (hematology, chemistry, urinalysis) or with Safety Values of Potential Clinical Concern (see Table 3).
* Diastolic blood pressure \> 105 mmHg at screen or baseline.
* Any signs or symptoms that are, in the Investigator's judgment, medically significant, in that they would impact the patient's safety.
* Patients with a QTc value of 460 ms or greater.
* Patients who are known to be allergic or hypersensitive to paroxetine and EB-1010.
* Patients previously treated with and not responding to paroxetine
* Monoamine oxidase inhibitors (e.g., Nardil, phenelzine, Parnate, tranylcypromine, Marplan, isocarboxazide) treatment within the 2 weeks prior to enrollment.
* Patients who would likely require prohibited concomitant medications and/or other depression treatment during the trial.
* Prisoners or subjects who are involuntarily incarcerated.
* Subjects who are compulsorily detained for treatment of either a psychiatric or physical (e.g., infectious disease) illness.
* Patients who demonstrate a 25% or greater decrease in depressive symptoms as reflected by the QIDS-SR19 total score from screen visit to baseline visit.
* Patients who plan to have elective surgeries during the course of the study.
* Patients with a history of antidepressant-induced hypomania or dysphoria.
* Patients who demonstrate a less than 80% compliance (as measured by pill count) of their antidepressant medication during the Screening Phase.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Euthymics BioScience, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pierre Tran, MD
Role: STUDY_DIRECTOR
Euthymics BioScience, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pacific Clinical Research Medical Group
Arcadia, California, United States
Southwest Research, Inc.
Beverly Hills, California, United States
Synergy Clinical Research Center
National City, California, United States
Clinical Innovations, Inc.
Santa Ana, California, United States
Pacific Clinical Research Medical Group
Upland, California, United States
Radiant Research, Inc.
Denver, Colorado, United States
Comprehensive Psychiatric Care
Norwich, Connecticut, United States
Sanitas Research
Coral Gables, Florida, United States
Clinical Neuroscience Solution, Inc.
Jacksonville, Florida, United States
Florida Clinical Research Center
Maitland, Florida, United States
Clinical Neuroscience Solutions, Inc
Orlando, Florida, United States
Medical Research Group of Central Florida
Sanford, Florida, United States
Atlanta Center for Medical Research
Atlanta, Georgia, United States
AMR Baber Research
Naperville, Illinois, United States
Psychiatric Medicine Associates
Stokie, Illinois, United States
Lake Charles Clinical Trials
Lake Charles, Louisiana, United States
Clinical Insights
Glen Burnie, Maryland, United States
Cambridge Health Alliance
Cambridge, Massachusetts, United States
AccelRx Research
Fall River, Massachusetts, United States
St Charles Psychiatric Associates
Saint Charles, Missouri, United States
Global Medical Institutes
Princeton, New Jersey, United States
CRI Worldwide, LLC
Willingboro, New Jersey, United States
Mount Sinai School of Medicine
New York, New York, United States
Behavioral Medical Research of Staten Island
Staten Island, New York, United States
Community Research
Cincinnati, Ohio, United States
Midwest Clinical Research Center
Dayton, Ohio, United States
North Star Medical Research
Middleburg Heights, Ohio, United States
Neurology and Neuroscience Center of Ohio
Toledo, Ohio, United States
SP Research, PLLC
Oklahoma City, Oklahoma, United States
Lehigh Valley Hospital
Allentown, Pennsylvania, United States
Southeastern PA Medical Institute
Broomall, Pennsylvania, United States
Suburban Research Associates
Media, Pennsylvania, United States
University of Pennsylvania
Philadelphia, Pennsylvania, United States
CRI Worldwide
Philadelphia, Pennsylvania, United States
Scranton Counseling Center
Scranton, Pennsylvania, United States
Radiant Research
Greer, South Carolina, United States
Clinical NeuroScience Solutions, Inc.
Memphis, Tennessee, United States
Vanderbilt University Medical Center
Nashville, Tennessee, United States
FutureSearch Trials of Dallas
Dallas, Texas, United States
Radiant Research, Inc.
Murray, Utah, United States
Aspen Clinical Research
Orem, Utah, United States
VCU
Richmond, Virginia, United States
Dean Foundation for Health, Research & Education
Middleton, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EB-1010-301
Identifier Type: -
Identifier Source: org_study_id